Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Rifampin in New, Smear-Positive TB
NCT01408914Phase 2Completed
- Sponsor
- Harvard Medical School
- Start
- Sep 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of rifampicin in pulmonary tuberculosis (TB), sponsored by Harvard Medical School. Started Sep 2013; status: completed.
02
Drugs
rifampicin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT01408914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01408914.